BRIEF-Benitec Biopharma Reports Positive Interim Clinical Trial Data For First OPMD Subject Treated With BB-301 In Phase 1b/2a Study

Reuters04-18

April 18 (Reuters) - Benitec Biopharma Inc :

* BENITEC BIOPHARMA REPORTS POSITIVE INTERIM CLINICAL TRIAL DATA FOR FIRST OPMD SUBJECT TREATED WITH BB-301 IN PHASE 1B/2A STUDY

* BENITEC BIOPHARMA: FIRST EFFICACY SIGNALS DEMONSTRATED FOR GENE THERAPY UNDER DEVELOPMENT FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD)

* BENITEC BIOPHARMA INC: BB-301 FACILITATED IMPROVEMENTS ACROSS MULTIPLE MEASURES OF SWALLOWING FUNCTION IN FIRST PHASE 1B/2A CLINICAL STUDY SUBJECT

* BENITEC BIOPHARMA INC: BB-301 HAS BEEN GRANTED ORPHAN DRUG DESIGNATION BY US FDA AND EMA COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS $(COMP)$

* BENITEC BIOPHARMA INC: REGARDING BB-301 SAFETY PROFILE OBSERVED TO DATE, NO SERIOUS ADVERSE EVENTS HAVE BEEN OBSERVED FOR TWO SUBJECTS

Source text for Eikon: Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428560030?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-18 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2428560030","market":"us","top_or_hot":-1,"title":"BRIEF-Benitec Biopharma Reports Positive Interim Clinical Trial Data For First OPMD Subject Treated With BB-301 In Phase 1b/2a Study","media":"Reuters","content":"<html><body><p>April 18 (Reuters) - Benitec Biopharma Inc   :</p><p>   * BENITEC BIOPHARMA REPORTS POSITIVE INTERIM CLINICAL TRIAL DATA FOR FIRST OPMD SUBJECT TREATED WITH BB-301 IN PHASE 1B/2A STUDY</p><p>   * BENITEC BIOPHARMA: FIRST EFFICACY SIGNALS DEMONSTRATED FOR GENE THERAPY UNDER DEVELOPMENT FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD)</p><p>   * BENITEC BIOPHARMA INC: BB-301 FACILITATED IMPROVEMENTS ACROSS MULTIPLE MEASURES OF SWALLOWING FUNCTION IN FIRST PHASE 1B/2A CLINICAL STUDY SUBJECT</p><p>   * BENITEC BIOPHARMA INC: BB-301 HAS BEEN GRANTED ORPHAN DRUG DESIGNATION BY US FDA AND EMA COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS <a href=\"https://laohu8.com/S/COMP\">$(COMP)$</a></p><p>   * BENITEC BIOPHARMA INC: REGARDING BB-301 SAFETY PROFILE OBSERVED TO DATE, NO SERIOUS ADVERSE EVENTS HAVE BEEN OBSERVED FOR TWO SUBJECTS</p><p>Source text for Eikon:    Further company coverage:   </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Benitec Biopharma Reports Positive Interim Clinical Trial Data For First OPMD Subject Treated With BB-301 In Phase 1b/2a Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Benitec Biopharma Reports Positive Interim Clinical Trial Data For First OPMD Subject Treated With BB-301 In Phase 1b/2a Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-18 20:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 18 (Reuters) - Benitec Biopharma Inc   :   * BENITEC BIOPHARMA REPORTS POSITIVE INTERIM CLINICAL TRIAL DATA FOR FIRST OPMD SUBJECT TREATED WITH BB-301 IN PHASE 1B/2A STUDY   * BENITEC BIOPHARMA:...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTC","symbol_name":"Benitec Biopharma Limited","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2428560030","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428560030","pubTimestamp":1713442196,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 18  - Benitec Biopharma Inc   :   * BENITEC BIOPHARMA REPORTS POSITIVE INTERIM CLINICAL TRIAL DATA FOR FIRST OPMD SUBJECT TREATED WITH BB-301 IN PHASE 1B/2A STUDY   * BENITEC BIOPHARMA: FIRST EFFICACY SIGNALS DEMONSTRATED FOR GENE THERAPY UNDER DEVELOPMENT FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY    * BENITEC BIOPHARMA INC: BB-301 FACILITATED IMPROVEMENTS ACROSS MULTIPLE MEASURES OF SWALLOWING FUNCTION IN FIRST PHASE 1B/2A CLINICAL STUDY SUBJECT   * BENITEC BIOPHARMA INC: BB-301 HAS BEEN GRANTED ORPHAN DRUG DESIGNATION BY US FDA AND EMA COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS    * BENITEC BIOPHARMA INC: REGARDING BB-301 SAFETY PROFILE OBSERVED TO DATE, NO SERIOUS ADVERSE EVENTS HAVE BEEN OBSERVED FOR TWO SUBJECTSSource text for Eikon:    Further company coverage:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNTC":"Benitec Biopharma Limited","BB":"黑莓","BK4097":"系统软件","BK4139":"生物科技","COMP":"Compass, Inc.","BK4079":"房地产服务","BK4547":"WSB热门概念","BK4539":"次新股"},"translate_title":"简报-Benitec Biopharma报告首位接受BB-301治疗的OPMD受试者在1b/2a期研究中的中期临床试验数据呈阳性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BB":1,"BNTC":1,"COMP":1},"content_text":"April 18 (Reuters) - Benitec Biopharma Inc   :   * BENITEC BIOPHARMA REPORTS POSITIVE INTERIM CLINICAL TRIAL DATA FOR FIRST OPMD SUBJECT TREATED WITH BB-301 IN PHASE 1B/2A STUDY   * BENITEC BIOPHARMA: FIRST EFFICACY SIGNALS DEMONSTRATED FOR GENE THERAPY UNDER DEVELOPMENT FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD)   * BENITEC BIOPHARMA INC: BB-301 FACILITATED IMPROVEMENTS ACROSS MULTIPLE MEASURES OF SWALLOWING FUNCTION IN FIRST PHASE 1B/2A CLINICAL STUDY SUBJECT   * BENITEC BIOPHARMA INC: BB-301 HAS BEEN GRANTED ORPHAN DRUG DESIGNATION BY US FDA AND EMA COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS $(COMP)$   * BENITEC BIOPHARMA INC: REGARDING BB-301 SAFETY PROFILE OBSERVED TO DATE, NO SERIOUS ADVERSE EVENTS HAVE BEEN OBSERVED FOR TWO SUBJECTSSource text for Eikon:    Further company coverage:","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428560030"}